ArriVent BioPharma (AVBP) Stock Price, News & Analysis

Company Overview

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Key Stats

• Today's Range: $17.31 to $18.61
• 50-Day Range: $16.95 to $22.72
• 52-Week Range: $15.47 to $36.37
• Volume: 174,730 shs
• Average Volume: 268,870 shs
• Market Capitalization: $754.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.14
• Consensus Rating: Buy

ArriVent BioPharma Stock Analysis - MarketRank™

ArriVent BioPharma scored higher than 41% of companies evaluated by MarketBeat, and ranked 665th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

ArriVent BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

ArriVent BioPharma has a consensus price target of $39.14, representing about 113.9% upside from its current price of $18.30.

Amount of Analyst Coverage

ArriVent BioPharma has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for ArriVent BioPharma are expected to decrease in the coming year, from ($2.74) to ($3.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ArriVent BioPharma is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ArriVent BioPharma is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ArriVent BioPharma has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.80% of the float of ArriVent BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ArriVent BioPharma has a short interest ratio ("days to cover") of 19.9, which indicates bearish sentiment.

Change versus previous month

Short interest in ArriVent BioPharma has recently increased by 1.49%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ArriVent BioPharma does not currently pay a dividend.

Dividend Growth

ArriVent BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

22.80% of the float of ArriVent BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ArriVent BioPharma has a short interest ratio ("days to cover") of 19.9, which indicates bearish sentiment.

Change versus previous month

Short interest in ArriVent BioPharma has recently increased by 1.49%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: N/A

News Sentiment

ArriVent BioPharma has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for ArriVent BioPharma this week, compared to 3 articles on an average week.

Search Interest

8 people have searched for AVBP on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.58% of the stock of ArriVent BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 9.48% of the stock of ArriVent BioPharma is held by institutions.

AVBP Stock Analysis - Frequently Asked Questions

How have AVBP shares performed this year?

ArriVent BioPharma's stock was trading at $26.64 at the start of the year. Since then, AVBP shares have decreased by 31.3% and is now trading at $18.30.

How were ArriVent BioPharma's earnings last quarter?

ArriVent BioPharma, Inc. (NASDAQ:AVBP) released its quarterly earnings results on Monday, August, 11th. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.20.

When did ArriVent BioPharma IPO?

ArriVent BioPharma (AVBP) raised $175 million in an initial public offering on Friday, January 26th 2024. The company issued 9,722,222 shares at a price of $18.00 per share.

Who are ArriVent BioPharma's major shareholders?

ArriVent BioPharma's top institutional investors include Octagon Capital Advisors LP (4.80%), Geode Capital Management LLC (1.74%), Fund 1 Investments LLC (1.30%) and Squarepoint Ops LLC (0.50%). Insiders that own company stock include Hillhouse Investment Managemen and Orbimed Advisors Llc.
View institutional ownership trends.

How do I buy shares of ArriVent BioPharma?

Shares of AVBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ArriVent BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ArriVent BioPharma investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), Opendoor Technologies (OPEN), Tesla (TSLA), JPMorgan Chase & Co. (JPM), NVIDIA (NVDA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/22/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVBP
• Previous Symbol: NASDAQ:AVBP
• CIK: 1868279
• Web: www.arrivent.com
• Phone: 628-277-4836
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ArriVent BioPharma: $39.14
• High Price Target: $45.00
• Low Price Target: $33.00
• Potential Upside/Downside: +121.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -55.40%
• Return on Assets: -51.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.74
• Quick Ratio: 12.74

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.65 per share
• Price / Book: 2.31

Miscellaneous

• Outstanding Shares: 40,570,000
• Free Float: 33,031,000
• Market Cap: $716.06 million
• Optionable: N/A
• Beta: 1.17